|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rearrangements of T- and B-cell receptor (TCR and BCR) genes are useful markers for clonality assessment as well as for minimal residual disease (MRD) monitoring during the treatment of haematological malignancies.
|
31587259 |
2020 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Pre- and posttreatment biopsies from 20 lesional skin samples of 18 patients with mycosis fungoides who received either 8 Gy LDRT (<i>n</i> = 16) or topical steroids (<i>n</i> = 4) underwent high-throughput T-cell receptor sequencing of the TCRB gene to quantify the malignant T-cell clone.
|
31636100 |
2020 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rearrangements of T- and B-cell receptor (TCR and BCR) genes are useful markers for clonality assessment as well as for minimal residual disease (MRD) monitoring during the treatment of haematological malignancies.
|
31587259 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through the profiling of the TCR repertoire in RA patients receiving different biologic medications, our study indicated an inverse tendency between TCR repertoire diversity and disease activity after biologic treatment in RA patients.
|
31360262 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, a defect in TCR-proximal signaling leads to lupus-like systemic autoimmunity under the specific genetic background that facilitates Tfh development.
|
31019063 |
2019 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An analysis of the TCR repertoire shows alterations that mostly affect the TCRα variable (TRAV) locus with specific VJ combinations and CDR3α sequences that are absent in <i>Rras2<sup>-/-</sup></i> mice, suggesting their involvement in autoimmunity.
|
31324740 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR -T cells or CAR- NK cells containing full length CS1 or the signaling domain of 2B4 with TCR-ζ have shown promising results to treat cancer and autoimmune diseases.
|
30347240 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mucosal-associated invariant T (MAIT) cells, which are enriched in human blood and express a semi-invariant TCR chain, play important roles in conditions such as infectious diseases and cancer.
|
30838000 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
|
31396932 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy.
|
31315298 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR -T cells or CAR- NK cells containing full length CS1 or the signaling domain of 2B4 with TCR-ζ have shown promising results to treat cancer and autoimmune diseases.
|
30347240 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The development of cancers in immunosuppressed patients has demonstrated the contribution of different T cell populations, including CD4<sup>+</sup> cells, in the control of cancer occurrence.Whereas absolute numbers of neutrophils, platelets and red blood cells are routinely monitored in clinic following treatments, because of possible short-term complications, absolute lymphocyte counts (ALC), their subpopulations or diversity (phenotype, TCR) are rarely analyzed and never used to choose therapy or as prognostic criteria.
|
30922400 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
|
30798772 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fueling the current excitement of cancer medicine includes also TCR- T cells, TCR-like antibodies, cancer vaccines and oncolytic viruses.
|
31703740 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
|
30642983 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The application of human TCR in cancer immunotherapy has gained momentum with developments in tumor killing strategies using endogenous adaptive immune responses.
|
30919413 |
2019 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we systematically analyzed changes of the TCRβ repertoire driven by EAE and pregnancy using TCR sequencing.
|
31444265 |
2019 |
|
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, when co-transferred with myelin-specific 2D2 TCR-transgenic naive T cells, unrelated OT-II TCR-transgenic memory-like T<sub>H</sub>17 cells infiltrate the spinal cord and produce IL-17A, interferon (IFN)-γ, and GM-CSF, increasing the susceptibility of the recipients to experimental autoimmune encephalomyelitis in an IL-1 receptor-dependent manner.
|
30755603 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemia fusion gene analysis demonstrated positive EVI1 and negative IgH and TCR gene rearrangement.
|
30608452 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
The percentage of TCR Vβ subfamily T cells was predominately lower in most AML cases, while it was increased in some cases.
|
31136687 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A defect in TCR-proximal signaling is a major characteristic of CD4 T cells in systemic lupus erythematosus; however, it is not fully known how defects in TCR signaling lead to lupus-like systemic autoimmunity characterized by germinal center development and autoantibody production against nuclear Ags.
|
31019063 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a 59-year-old woman with profound subacute bilateral SNHL including unilateral deafness after immunotherapy based on TCR gene therapy using modified T cells recognizing melanoma antigen recognized by T cells 1 for disseminated melanoma.
|
31295198 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological blockade of α<sub>1</sub>-adrenoceptor is shown to influence development of experimental autoimmune encephalomyelitis (EAE), an IL-17-producing CD4+TCR+ (Th17) cell-mediated disease mimicking multiple sclerosis.
|
31396845 |
2019 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
The testable inference of the mature T-cell theory is the clonality of MF with respect to all rearranged T-cell receptor (TCR) genes.
|
31515249 |
2019 |